UNSPSC 51352213: Hexestrol monomethyl ether

This classification denotes a non-steroidal estrogen with the molecular formula C19H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B1LXH6RPPM, chemically known as phenol, 4-(1-ethyl-2-(4-methoxyphenyl)butyl)-, (r*,s*)-, but more generally known as hexestrol monomethyl ether, which bears US NIH Compound Identifier 11954178. European Medicines Agency schedules hexestrol monomethyl ether or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08036MIG.

Most nations, for tariff purposes, schedule hexestrol monomethyl ether under HS 29072900. SMILES: CC[C@@H](C1CCC(CC1)O)[C@H](CC)C2CCC(CC2)OC.

UNSPSC 51352213 Hexestrol monomethyl ether is a Commodity code covering a specific pharmaceutical active ingredient used in manufacturing, though state and local procurement activity under this code is minimal. The recent solicitation tagged to this code—a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—does not target hexestrol monomethyl ether specifically but rather establishes a broad framework contract for manufacturers of generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.). The RFP seeks manufacturers certified under current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA) to supply identified pharmaceutical products by National Drug Code, with vendors required to maintain relationships with at least two of three authorized wholesalers and support multiple pricing models including flat price, net price formats, and WAC-minus structures. State and local governments do not appear to procure hexestrol monomethyl ether as a standalone commodity; the tagging of this code to a broad pharmaceutical framework contract suggests either a taxonomy misalignment or use of the code as a catch-all for individual active ingredients within multi-source generic pharmaceuticals.

The MMCAP RFP, administered by the Minnesota Department of Administration's Office of State Procurement, was posted January 20, 2026, with proposals due March 26, 2026, and covers participating state and local facilities in Minnesota and Oregon. Evaluation weights price competitiveness at 75 percent, with 10 percent on fixed pricing, 5 percent each on administrative fee data format compliance, EDI capability, and agreement to a 3 percent administrative fee. Contract awards are effective July 1, 2026, for a two-year term with optional extensions, and no specific set-aside designations or budget ceiling is disclosed in the available documentation. Given the absence of targeted recent activity for hexestrol monomethyl ether as a distinct procurement line item, this code warrants watch status only; opportunities in generic pharmaceutical manufacturing under MMCAP or similar state cooperative vehicles typically flow through broader family or class codes rather than individual commodity codes.